LGC Acquires Toronto Research Chemicals

LGC announced the acquisition of a majority stake in Toronto Research Chemicals (TRC), a manufacturer and supplier of synthetic organic bio-chemicals which are used as reference standards, research tools and building blocks by a global customer base across the pharmaceutical, applied and research sectors.

TRC has a product portfolio with over 46,000 compounds held in inventory and a wide breadth of synthetic and analytical chemistry capabilities. Founded in 1982 by David and Charles Dime, TRC has over 375 employees and operates from c.120,000 square foot of space across two manufacturing sites in Toronto.

TRC’s Chief Executive Charles Dime will remain a significant shareholder alongside LGC.

“We are delighted to partner with TRC to deliver the next phase of growth in the business and expansion of capabilities in Toronto,” Euan O’Sullivan, Managing Director, LGC’s Standards division, said. “We have enjoyed a long and successful relationship with TRC and this transaction strengthens our presence in the reference standards market, in particular in North America and Asia Pacific, as well as our ability to serve pharmaceutical and biotech customers. As we start combining our teams, we look forward to providing an extended portfolio of reference standards, research tools and building blocks to our customers around the world.”

“We are excited to be partnering with LGC and continuing to provide our customers with high quality products and services. Over the years, we have built a strong reputation as a supplier of choice for customers globally and look forward to strengthening our capabilities and product offering alongside LGC,” David and Charles Dime, Co-Founders, TRC, said.

  • <<
  • >>

Join the Discussion